| External factors: | SHR6390 |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Breast cancer |
| Experiment: | Flow cytometry//SA-β-gal activity assay |
| Description: | Accordingly, SHR6390 induced a concentration- dependent G1- phase cell cycle arrest in RB- positive MCF7 and ZR- 75- 1 breast cell lines.The proportion of senescence SA- β- gal positive cells increased from control levels of 10.6%- 74.4% and 77.0% by 1 μmol/L SHR6390 and 1 μmol/L palbociclib in MCF7 cells, respectively. SA- β- gal positive cells increased from 18.0% to 85.8% and 88.6% after SHR6390 and palbociclib treatment in ZR- 75- 1 cells, respectively. |
| Regulatory pathway: | CDK4/6-Rb |
| R-EF-Pathway: | Downregulation |
| Pathway experiment: | Western blot |
| Pathway description: | SHR6390 prominently reduced RB expression .SHR6390 also inhibited RB phosphorylation in the MCF7/TR cell line, implying that RB protein- related changes are a universal phenomenon associated with CDK4/6 inhibitor treatment. |
Annotation: